# EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19

> **NCT04822818** · PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 96 (actual)

## Conditions studied

- Corona Virus Infection
- SARS (Severe Acute Respiratory Syndrome)
- Virus Diseases
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases

## Interventions

- **DRUG:** BEVA+SOC
- **DRUG:** SOC

## Key facts

- **NCT ID:** NCT04822818
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-17
- **Primary completion:** 2022-04-10
- **Final completion:** 2022-07-11
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2022-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04822818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04822818, "EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04822818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*